Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML)

HOUSTON , June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a

Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant Expense-reduction Measures to Extend Cash Runway HOUSTON , March 22, 2024 (GLOBE NEWSWIRE) -- Salarius

Company implementing a series of cost-savings measures designed to extend Salarius’ expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from the ongoing Phase 1/2 clinical trials in hematologic cancers and Ewing sarcoma HOUSTON , Feb.

Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON , Jan. 16, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , announces that the U.S.

Additional Ewing Sarcoma Patient in Company’s Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and Cyclophosphamide Reaches 60% HOUSTON , Jan. 03, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals,